Literature DB >> 15187659

Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach.

Mohamed H El-Bradey1, Lingyun Cheng, Mi-Kyoung Song, Francesca J Torriani, William R Freeman.   

Abstract

PURPOSE: To evaluate the results of a graded treatment approach in a cohort of eyes with macular complications of immune recovery uveitis.
METHODS: A cohort of 18 eyes of 13 patients representing all eyes with these complications at the University of California, San Diego AIDS Ocular Treatment Unit was studied. Eyes were classified into three groups and treated according to a graded protocol.
RESULTS: Eyes with mild disease (macular edema and vision of 20/30 or better) were observed. These six eyes maintained good vision with only one dropping to 20/40. In eyes with worse macular edema and vision of 20/30 or worse (10 eyes of 9 patients), repository sub-Tenon steroid injections were used repeatedly. There were no complications of steroid use but visual improvement occurred in only 40% of eyes. Macular edema persisted. In eyes with structural macular changes, such as epiretinal membrane, vitrectomy resulted in vision improvement in three of four eyes. The cystoid macular edema persisted despite surgery.
CONCLUSION: Mild cases of immune recovery uveitis and macular edema may be observed. In eyes with reduction of vision due to cystoid macular edema, there was only a modest treatment effect using repository corticosteroids. Eyes with immune recovery uveitis that develop epiretinal membrane undergo some visual improvement after removal of the membrane. The macular edema of immune recovery uveitis is resistant to corticosteroid treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187659      PMCID: PMC1378115          DOI: 10.1097/00006982-200406000-00007

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  19 in total

1.  Immune recovery uveitis.

Authors:  J P Dunn
Journal:  Hopkins HIV Rep       Date:  2001-11

Review 2.  Immune recovery uveitis.

Authors:  B D Kuppermann; G N Holland
Journal:  Am J Ophthalmol       Date:  2000-07       Impact factor: 5.258

3.  Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy.

Authors:  Douglas A Jabs; Mark L Van Natta; John H Kempen; Peter Reed Pavan; Jennifer I Lim; Robert L Murphy; Larry D Hubbard
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

4.  Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome.

Authors:  M P Karavellas; C Y Lowder; C Macdonald; C P Avila; W R Freeman
Journal:  Arch Ophthalmol       Date:  1998-02

5.  Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis.

Authors:  M E Zegans; R C Walton; G N Holland; J J O'Donnell; M A Jacobson; T P Margolis
Journal:  Am J Ophthalmol       Date:  1998-03       Impact factor: 5.258

6.  Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes.

Authors:  M P Karavellas; S P Azen; J C MacDonald; C L Shufelt; C Y Lowder; D J Plummer; B Glasgow; F J Torriani; W R Freeman
Journal:  Retina       Date:  2001       Impact factor: 4.256

7.  Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy.

Authors:  Q D Nguyen; J H Kempen; S G Bolton; J P Dunn; D A Jabs
Journal:  Am J Ophthalmol       Date:  2000-05       Impact factor: 5.258

8.  Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis.

Authors:  M P Karavellas; M Song; J C Macdonald; W R Freeman
Journal:  Am J Ophthalmol       Date:  2000-07       Impact factor: 5.258

9.  Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression.

Authors:  D R Hoover; Y Peng; A Saah; R Semba; R R Detels; C R Rinaldo; J P Phair
Journal:  Arch Ophthalmol       Date:  1996-07

10.  Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome.

Authors:  B D Kuppermann; J G Petty; D D Richman; W C Mathews; S C Fullerton; L S Rickman; W R Freeman
Journal:  Am J Ophthalmol       Date:  1993-05-15       Impact factor: 5.258

View more
  7 in total

Review 1.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

Review 2.  Ophthalmologic Disease in HIV Infection: Recent Changes in Pathophysiology and Treatment.

Authors:  Michael W Stewart
Journal:  Curr Infect Dis Rep       Date:  2017-10-19       Impact factor: 3.725

3.  Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series.

Authors:  Yiwen Qian; Luoziyi Wang; Jing Jiang; Jinshan Suo; Huan Weng; Xin Che; Hongzhou Lu; Zhiliang Wang
Journal:  Front Med (Lausanne)       Date:  2022-04-27

4.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

5.  Immune recovery uveitis in HIV patients with cytomegalovirus retinitis in the era of HAART therapy-a 5-year study from Singapore.

Authors:  Tun Hang Yeo; Tun Kuan Yeo; Elizabeth P Wong; Rupesh Agrawal; Stephen C Teoh
Journal:  J Ophthalmic Inflamm Infect       Date:  2016-11-07

Review 6.  Management of patients with the immune reconstitution inflammatory syndrome.

Authors:  Suzaan Marais; Robert J Wilkinson; Dominique J Pepper; Graeme Meintjes
Journal:  Curr HIV/AIDS Rep       Date:  2009-08       Impact factor: 5.495

Review 7.  Immune recovery uveitis: pathogenesis, clinical symptoms, and treatment.

Authors:  Beata Urban; Alina Bakunowicz-Łazarczyk; Marta Michalczuk
Journal:  Mediators Inflamm       Date:  2014-06-24       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.